Ligand-Receptor Interactions and Drug Design

Abstract

This supplement is intended to focus on ligand-receptor interactions and drug design. Biochemistry of ligand binding, experimental drug design and computational drug design are included within the supplement's scope. Biochemistry Insights aims to provide researchers working in this complex, quickly developing field with online, open access to highly relevant scholarly articles by leading international researchers. In a field where the literature is ever-expanding, researchers increasingly need access to up-to-date, high quality scholarly articles on areas of specific contemporary interest. This supplement aims to address this by presenting high-quality articles that allow readers to distinguish the signal from the noise. The editor in chief hopes that through this effort, practitioners and researchers will be aided in finding answers to some of the most complex and pressing issues of our time. Articles should focus on ligand-receptor interactions and drug design and may include the following topics: § § Biochemistry of ligand binding § § Amphiphilic drugs, binding mechanism, biding modes, binding properties, bispecific ligands, drug targets, drug-drug interactions, electrostatic interactions, endocrine receptors, hydrogen bonding, hydrophobic interactions, intermolecular interactions, ligand activation, ligand binding affinity, ligand conformers, ligand specificity, ligand-directed signaling, ligand-protein conjugates, ligand-selective activity, ligand-specific binding, lipophilicity, molecular conservation, molecular recognition, multi-mode ligand-receptor interactions, molecular scaffolds, multiple ligand recognition, multivalent ligand-receptor interactions, nuclear receptor ligands, nuclear receptors, polar contacts, receptor inhibition, quantum chemical-based drug-receptor interaction, receptor modulators, structural conservation, target-ligand interface, universal ligand. § § Experimental drug design § § Affinity purification, apoptosis-mediating receptor-ligand systems, clinical pharmacokinetics, cofactor discovery, differential mass spectrometry, differential scanning fluorimetry, drug screening, fluorescence interference detection, fluorescent ligand, high-throughput assays, in vivo chemical crosslinking, live zebra-fish-based screening system, mutational analysis, myocardial perfusion imaging, plant-derived ligands, radiolabeled ligand interactions, receptor imaging, spectrometry, time resolved FRET strategy. § § Computational drug design § § Chemocentric informatics approach, computational modeling, computer-assisted design, evolutionary design of ligands, in silico approaches, knowledge-based scoring functions, molecular docking, prediction of ligand binding, prediction of ligand-induced structural polymorphism, quantitative structure-activity relationships, rational approach to drug design, rationally designed mutations, structure-guided drug design, structure-based design, virtual screening.